Literature DB >> 2901225

The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1.

B A Brooks1, O W McBride, C T Dolphin, M Farrall, P J Scambler, F J Gonzalez, J R Idle.   

Abstract

CYP3, the gene which encodes the hepatic cytochrome P450pcn1, the isozyme responsible for the metabolic oxidation of the calcium channel-blocking drug nifedipine, has recently been mapped to human chromosome 7 using somatic cell hybrids. Using multilocus linkage analysis in CEPH families, we examined the linkage of a cDNA probe (hPCN1) for CYP3 to the oncogene MET, the pro-alpha 2(1) collagen gene COL1A2, and the T-cell receptor beta-chain gene TCRB, together with three arbitrary loci D7S8, D7S13, and D7S16, defined by the anonymous DNA probes pJ3.11, pB79a, and p7C22, respectively. From 70 CEPH parents screened with a StyI RFLP for hPCN1, four informative families were found each with both parental and maternal grandparents and 6-11 children per family. Tight linkage emerged between CYP3 and COL1A2, with a maximum combined lod score of 5.72 at theta = 0, suggesting the most likely subchromosomal localization of CYP3 is 7q21.3-q22.1.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901225      PMCID: PMC1715388     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  21 in total

Review 1.  Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.

Authors:  J R Idle; R L Smith
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

2.  Refined linkage map of chromosome 7 in the region of the cystic fibrosis gene.

Authors:  G M Lathrop; M Farrall; P O'Connell; B Wainwright; M Leppert; Y Nakamura; N Lench; H Kruyer; M Dean; M Park
Journal:  Am J Hum Genet       Date:  1988-01       Impact factor: 11.025

Review 3.  Inherited defects of hepatic drug metabolism.

Authors:  A Küpfer; R Preisig
Journal:  Semin Liver Dis       Date:  1983-11       Impact factor: 6.115

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Polymorphic drug oxidation in humans.

Authors:  M Eichelbaum
Journal:  Fed Proc       Date:  1984-05-15

7.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

8.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  7 in total

Review 1.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M R Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Mouse chromosome 6.

Authors:  R W Elliott; K J Moore
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 3.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

4.  CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Authors:  Vibha Bhatnagar; Erin P Garcia; Daniel T O'Connor; Victoria H Brophy; John Alcaraz; Erin Richard; George L Bakris; John P Middleton; Keith C Norris; Jackson Wright; Leena Hiremath; Gabriel Contreras; Lawrence J Appel; Michael S Lipkowitz
Journal:  Am J Nephrol       Date:  2009-11-12       Impact factor: 3.754

5.  Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif.

Authors:  J M Huss; S I Wang; A Astrom; P McQuiddy; C B Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

6.  Phylogenetic analysis of the cytochrome P450 3 (CYP3) gene family.

Authors:  Andrew G McArthur; Tove Hegelund; Rachel L Cox; John J Stegeman; Mette Liljenberg; Urban Olsson; Per Sundberg; Malin C Celander
Journal:  J Mol Evol       Date:  2003-08       Impact factor: 2.395

7.  Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates.

Authors:  Miriam Saiz-Rodríguez; Susana Almenara; Marcos Navares-Gómez; Dolores Ochoa; Manuel Román; Pablo Zubiaur; Dora Koller; María Santos; Gina Mejía; Alberto M Borobia; Cristina Rodríguez-Antona; Francisco Abad-Santos
Journal:  Biomedicines       Date:  2020-04-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.